


The Searle Company Limited

Corporate briefing 2022





Subsidiaries of Searle



Our Footprints

SEARLE

EXCELLENCE IN COMMERCIAL OPERATIONS



- Cardiovascular
- Pain Management
- iii. Gynae
- Cough Suppressant
- Anaemia

No.



- Pulmonology
- Neurology and Pediatrics



ND



- Largest Pharmaceutical Company In terms of Product Consumptions(Unit)

- Exporter in Pakistan

Everyday

>539,000



Prescriptions are prescribed by Doctors



A Passionate Team of

Medical Sales Professionals Serving the Nation



Billion Rupee Club



500 Million Plus Club



CAGR 5 YR

Growing with Double Digit on 5 yr horizon

Achievements

COMMITMENT TO EXCELLENCE



Searle was ranked as the most outstanding company in Healthcare sector of Pakistan as per Asiamoney's Outstanding Companies Poll, 2018 & 2021.



Searle has been part of Forbes Asia's Best Under A Billion rankings from 2017 to 2019.




Searle won Asia's Best Performing Companies 2021, category of Asia Corporate Excellence & Sustainability Awards.






Pharmaceutical Industry

The pharmaceutical sector recorded revenue of PKR 678bn (USD 3.5 bn) in last 12 months with YoY growth of 15.29% (against PKR 588bn in last year).





Our Product Portfolio



MARKETING AUTHORIZATION















Our Brands

LEADING BRANDS IN THEIR THERAPEUTIC AREA

Cough	Hydryllin
Muscle Relaxant	• Nuberol
ORS	• Peditral
Cardiovascular	• Extor, Spiromide, Byscard
Analgesic	• Tramal, Rotec
Gastrointestinal	Gravinate, Lomotil, Selanz
Antibiotics	• Negram
Anaemia	• Venofer
Eye care	• Cosopt, Trusopt



Our Partners

TRUST OF OUR AFFILIATORS




























































Our Presence

SEARLE

Export contributes 10% to our revenue






Industry Rankings


SEARLE IS RANKED NUMBER 2^{ND} IN TERMS OF VOLUME AND RANKEND 5^{TH} IN TERMS OF VALUE

2022 – VOI	LUME IMS MAT SEP		Market Share%	Growth %	2022 – VAI	LUE IMS MAT SEP	Market Share%	Growth %	CAGR %
GSK		367,871,446	10.32%	4.97	GETZ	42,833,844,495	6.32	16.13	15.87
SEARLE	231,573,000		6.49%	11.26	GSK	41,900,221,858	6.18	12.87	12.05
ABBOTT	228,644,531		6.41%	11.56	ABBOTT	40,573,836,687	5.98	16.08	14.65
SAMI	204,322,218		5.73%	8.93	SAMI	40,415,159,912	5.96	18.51	19.21
GSK CH	148,370,169		4.16%	9.04	SEARLE	38,470,012,733	5.67	19.03	17.59
GETZ	147,177,252		4.13%	8.22	MARTIN DOW	26,717,546,448	3.94	11.57	13.72
MARTIN DOW	130,755,136		3.67%	0.44	HILTON	23,210,778,799	3.42	30.56	17.83
BARRETT HODGSON	109,530,390		3.07%	18.77	GSK CH	22,364,768,991	3.30	15.82	22.48
ATCO	107,361,635		3.01%	8.64	HIGH-Q	20,803,409,923	3.07	17.83	15.39
BOSCH	101,393,024		2.84%	8.60	BOSCH	18,740,726,258	2.76	10.00	15.19



Our Revenue & Profits







Corporate Social Responsibility

Our humble CSR efforts

- Considering the importance of education and believing it to be a right of every citizen, Searle supports The Citizens Foundation to help them achieve the cause, empowering children to become agents of positive change.
- Continuing with our philosophy of being a socially responsible organization and contributing to the economy we operate in; we support the cause of skilled Pakistan being carried on by Hunar Foundation by providing financial assistance.
- Facilitating the young doctors of today with their educational needs to become masters of tomorrow, Searle contributes by providing scholarships and assistance to students in form of books, educational material and online registrations to faculty members of hospitals.
- Searle feels proud to be a source of light in the lives of needy patients with critical medical conditions, by providing financial assistance for their treatments. Contribution towards AKAR hospital for the less privileged section of the society is also a part of our saving lives initiatives.
- Searle never lags behind in supporting the development of hospitals, as better hospitals and facilities help in accommodating more patients and helps the cause of healthier Pakistan. Our assistance to National Institute of Cardiovascular diseases, Shaukat Khanum, Sindh Institute of Urology and Transplantation and Indus hospital are examples of some of our initiatives.



















Our Collaboration



• IBA Karachi- established the Rashid Abdulla Consumer Neuroscience Lab



• NED University - established a research facility, Rashid Abdullah Research Centre



LUMS - Contributed to setup of MDR Laboratory



Karachi University - Research & Development Centre at ICCBS



Financial Information

Standalone

	2022	2021	2020
Revenue	17,737,282	16,569,596	16,567,219
SG&A %	34.45%	31.93%	29.65%
Operating profit %	23.98%	24.48%	23.82%
PAT %	11.79%	12.81%	14.82%
EPS	6.70	7.01	7.87
Cash Dividend	Nil	20.00%	25.00%
Stock Dividend	25.00%	30.00%	Nil

2022 2021 2020 29,909,659 26,219,656 20,474,842 Revenue 27.38% SG&A % 24.98% 25.67% Operating profit % 19.32% 24.74% 21.22% PAT % 8.08% 14.29% 12.44% **EPS** 7.54 12.15 8.17

Consolidated



Thank you